Editas Medicine, Inc. (EDIT) Form 8-K — Nov 9, 2026
Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share) on $10.4 million of collaboration revenue, up from $7.5 million a year ago on milestone recognition. Key pipeline news: Australia's HREC approved the Phase 1/2 Strive study of EDIT-401 in heterozygous familial hypercholesterolemia, with dosing expected this year and topline Part 1 data in H2 2027. New preclinical data showed ≥90% LDL-C reduction maintained over 10 months in non-human primates. A second IND/CTA was accepted under the Bristol Myers Squibb collaboration for BMS-986527, a CD70 allogeneic CAR-T therapy, triggering a milestone payment to Editas.
Key figures
- Revenue
- 10365000
- Revenue Yoy
- up from $7.5M to $10.4M for Q3
- Total Assets
- 219412000
- Cash Position
- 190200000
- Cash runway
- into second half of 2028
- Hefh us patients
- 1200000
- Ga expense q3 2026
- 13477000
- Nine month revenue
- 25086000
- Rd expense q3 2026
- 21170000
- Ldl c reduction nhp
- ≥90% maintained over 10 months
- Lpa apob reduction nhp
- ~90% mean over three months
- Weighted avg shares q3 2026
- 153604267
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.